Using multiplex CRISPR-Cas9 editing of human hematopoietic, or blood-forming, stem cells followed by transplantation in mice, researchers designed customized mouse models for the progression of leukemia. In a number of different experiments, the animal models successfully reflected human responses to a therapeutic agent commonly used to treat blood cancers.